Human Immunodeficiency Virus (HIV1) Infection Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034)

The human immunodeficiency virus (HIV1) infection market was valued at USD 19.62 Billion in 2024, driven by the increasing prevalence of HIV and advancements in antiretroviral therapies across the 8 major markets. The market is expected to grow at a CAGR of 5.20% during the forecast period of 2025-2034, with the values likely to reach USD 32.57 Billion by 2034 .

Human Immunodeficiency Virus (HIV1) Infection Market Overview

HIV-1 refers to the most common type of HIV (Human Immunodeficiency Virus) in which the virus attacks the immune system by destroying CD4 cells responsible for fighting infections in the body. A person with HIV can develop AIDS (Acquired Immune Deficiency Syndrome) at the most advanced stage of infection. The market for HIV-1 infection is driven by the rising burden of the disease and increasing access to treatment. The introduction of advanced antiretroviral therapies including long acting injectables like cabotegravir and rilpivirine further supports the market growth. Moreover, the increasing availability of cost-effective generic medications and regulatory support from health agencies are anticipated to influence market dynamics.

Human Immunodeficiency Virus (HIV1) Infection Market Growth Drivers

Increasing Prevalence of Human Immunodeficiency Virus Infection to Drive Market Growth

HIV poses a global public health concern and is estimated to have claimed 42.3 million lives to date. According to the World Health Organization (WHO), approximately 39.9 million individuals were affected by HIV at the end of 2023, with the WHO African Region accounting for 65% of the cases. Further, it was reported that 1.3 million people acquired the infection in 2023, and about 630,000 people died as a result of HIV-related causes. This increasing global prevalence of HIV is driving the demand for HIV medications and care services, which contributes to the market growth.

Human Immunodeficiency Virus Infection Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rise in Drug Approvals to Affect the Market Landscape Significantly

In March 2024, Johnson & Johnson's nonnucleoside reverse transcriptase inhibitor medication EDURANT PED received approval from the US Food and Drug Administration (FDA) to treat human immunodeficiency virus-1 (HIV-1) in children. EDURANT PED has shown efficacy in suppressing HIV-1 when given along with other antiretroviral therapies and has expanded treatment options for pediatric patients with HIV-1 RNA viral load lower than 100,000 copies per milliliter. The surge in regulatory approvals of effective medications for HIV treatment is poised to bolster the market growth in the coming years.

Growing Public Awareness Poised to Augment Human Immunodeficiency Virus (HIV1) Infection Market Demand

The market is witnessing increasing public health campaigns and educational initiatives that are leading to increased awareness of HIV, stimulating early diagnosis and treatment-seeking behavior. In addition, the expansion of HIV testing programs, including community-based testing and self-testing kits, is contributing to increased market demand.

Advancements in Antiretroviral Therapy to Elevate the Human Immunodeficiency Virus (HIV1) Infection Market Value

One of the significant market trends is the introduction of newer, more effective antiretroviral therapies with lower side effects and simplified dosing. This is anticipated to elevate the market value. For instance, long-acting injectable antiretroviral therapies, such as cabotegravir and rilpivirine, offer convenient dosing schedules and are gaining popularity among patients who do not want to take medication daily.

Increasing Availability of Generic Antiretroviral Therapies to Boost Human Immunodeficiency Virus (HIV1) Infection Market Size

As the patents for several first-generation antiretroviral medications are expiring, the market is experiencing a rising entry of their generic equivalents. These generics are more affordable and help in increasing access to treatment in lower-income and resource-limited settings, thereby contributing to market expansion.

Human Immunodeficiency Virus Infection Market Segmentation

Market Breakup by Drug Class

• Nucleoside-Analog Reverse Transcriptase Inhibitor
• Non-Nucleoside Reverse Transcriptase Inhibitor
• Protease Inhibitors
• Integrase Inhibitors
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by End User

• Hospitals
• Homecare Settings
• Specialty Centers
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Independent Pharmacies
• Online Pharmacies
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• India
• Japan

HIV-1 Infection Market Share

Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth

Based on the drug class, the market is segmented into nucleoside-analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors, among others. Nucleoside-analog reverse transcriptase inhibitors are one of the most widely used classes of antiretroviral drugs. They inhibit the reverse transcriptase enzyme which is needed for viral replication. Tenofovir disoproxil fumarate (tenofovir DF) is one such medication used in HIV-1 treatment. The availability of generic versions of nucleoside-analog reverse transcriptase inhibitors has made them widely accessible, even in low- and middle-income countries.

Human Immunodeficiency Virus (HIV1) Infection Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a major market for HIV-1 infection due to the high prevalence of HIV and the greater adoption rate of the latest antiretroviral therapies including single tablet formulations and long-acting injectables. Increased government initiatives in the form of public health policies and funding to improve access to HIV care and treatment further fuel the market growth. Further, the availability of affordable generic antiretroviral medications also supports market expansion in the region.

Leading Players in the Human Immunodeficiency Virus (HIV1) Infection Market

The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Cipla

Cipla Limited is a major pharmaceutical company headquartered in Mumbai, India, and is one of the leading players in the market. The company offers antiretroviral drugs in fixed-dose combinations and single-agent formulations. Cipla's antiretroviral medicine Tenvir-EM Tablet, containing a combination of Emtricitabine and Tenofovir disoproxil fumarate, is used for treating HIV infection.

Genentech Inc

Headquartered in South San Francisco, California, Genentech Inc. is a member of the Roche Group and is involved in HIV-1 research and treatment. Its prescription medicine FUZEON is used in combination with other antiretroviral drugs to treat Human Immunodeficiency Virus-1 (HIV-1) infection.

Gilead Sciences Inc

California-based Gilead Sciences Inc. is a research-based biopharmaceutical company with a prominent presence in the HIV treatment and prevention market. The company has developed 11 commercially available HIV drugs. It is actively involved in advancing the pipeline of next-generation therapeutic treatments.

AbbVie Inc

American pharmaceutical company AbbVie is known for its research and development of novel antiretroviral therapies. Its product NORVIR® (ritonavir) is a well-known treatment for HIV-1 infection.

Other key players in the market include Boehringer Ingelheim International Gmbh, ViiV Healthcare, Sanofi, and Bristol Myers Squibb.

Key Questions Answered in the Human Immunodeficiency Virus (HIV1) Infection Market Report

• What was the human immunodeficiency virus (HIV1) infection market value in 2024?
• What is the human immunodeficiency virus (HIV1) infection market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on drug class?
• What is the market breakup based on the route of administration?
• Who are the major end users in the market?
• What is the market breakup by distribution channel?
• What are the major factors aiding the human immunodeficiency virus (HIV1) infection market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do the prevalence and incidence of human immunodeficiency virus infection affect the market landscape?
• What are the major human immunodeficiency virus (HIV1) infection market trends?
• How do the advancements in antiretroviral therapy impact the market size?
• Which drug class will dominate the market share?
• Which route of administration is expected to have a high market value in the coming years?
• Which distribution channel will experience the highest demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the human immunodeficiency virus (HIV1) infection market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.